Aprea Other Friday, November 20, 2026 +0.50 Positive

Aprea reports Phase 1 data for WEE1 inhibitor APR-1051

Aprea announced interim Phase 1 results showing partial responses in uterine cancer patients, supporting continued dose optimization and the planned expansion into specific breast and ovarian cancer cohorts.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed